Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab)
Merck (MSD) · Achievement · November 13, 2026
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion on extending the use of ENFLONSIA to children up to 24 months old who are at risk for severe respiratory syncytial virus disease.
AntSpace’s summary of Merck (MSD)’s own announcement: read the original.